Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
1847 Goedeker (GOED)
PaxMedica (PXMD)
Vistas Media Acquisition (VMACU)
Yucaipa Acquisition (YAC.U)
Rackspace Technology, Inc. (RXT)
GO Acquisition (GOAC.U)
BigCommerce Holdings, Inc (BIGC)
Rocket Companies, Inc. (RKT)
Oak Street Health, Inc. (OSH)
Acutus Medical Inc (AFIB)
IBEX Holdings Limited (IBEX)
Checkmate Pharmaceuticals, Inc. (CMPI)
Freeline Therapeutics Holdings plc (FRLN)
Priced IPO
Fathom Holdings (FTHM)
Vital Farms, Inc. (VITL)
Vasta Platform Limited (VSTA)
AlloVir, Inc. (ALVR)
Li Auto Inc. (LI)
Vertex, Inc. (VERX)
iTeos Therapeutics, Inc. (ITOS)
Inozyme Pharma, Inc. (INZY)
Annexon, Inc. (ANNX)
Nurix Therapeutics, Inc. (NRIX)
Montrose Environmental Group, Inc. (MEG)
Skillful Craftsman Education Technology Ltd. (EDTK)
Jamf Holding Corp. (JAMF)
Renalytix AI plc (RNLX)
Berkeley Lights, Inc. (BLI)
Pandion Therapeutics, Inc. (PAND)
ALX Oncology Holdings Inc. (ALXO)
Trean Insurance Group, Inc. (TIG)
Relay Therapeutics, Inc. (RLAY)
GoHealth, Inc. (GOCO)
More companies

iTeos Therapeutics, Inc. (ITOS)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. They leverage their deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies. Their innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed to build on prior learnings in the field to have differentiated pharmacological and clinical profiles. Their most advanced product candidate, EOS-850, is designed as a highly selective small molecule antagonist of the adenosine A2a receptor, or A2AR, in the adenosine triphosphate, or ATP, adenosine pathway, a key driver of immunosuppression in the tumor microenvironment across a broad range of tumors. They are investigating EOS-850 in an open-label Phase 1/2a clinical trial in adult patients with advanced solid tumors and they have observed encouraging preliminary single-agent activity in the dose escalation portion of the trial. They expect to report initial data from monotherapy and combination therapy expansion cohorts in the first half of 2021. Their lead antibody product candidate, EOS-448, is an antagonist of TIGIT, or T-cell immunoreceptor with Ig and ITIM domains, a checkpoint that has a role in both inhibitory and stimulatory pathways in the immune system. EOS-448 was also designed to engage the Fc gamma receptor, or FcgR, to promote antibody-dependent cellular cytotoxicity, or ADCC, activity, including the elimination of tumor-infiltrating regulatory T cells, or Tregs. They have recently initiated an open-label Phase 1/2a clinical trial of EOS-448 in adult patients with advanced solid tumors and expect to report initial data in the first half of 2021. They retain worldwide rights to develop and commercialize all of their product candidates.
Industry
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
CEO CFO
Michel Detheux Matthew Gall
Employees Founded
46 2012

Contacts

Address: 139 Main Street, Cambridge, MA 02142, US

Telephone: (339) 217-0162

Web page: https://www.iteostherapeutics.com

IPO information

Expected Date 7/24/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $539.72
Revenues (MM) $0
Net Income (Loss) (MM) $-27.9

Voting

What do you think will happen with the ITOS share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 8.9
Shares Revised (MM) 10.6
Expected offer amount (MM) $151.3
Realized offer amount(MM) $201.4
Underwriters
JP Morgan/ SVB Leerink/ Piper Sandler
CO-Managers
Wedbush PacGrow

Sector: Healthcare

Tweets about $ITOS

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats